An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer
Crossref DOI link: https://doi.org/10.1007/s10637-014-0147-9
Published Online: 2014-08-26
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Pili, Roberto
Carducci, Michael
Brown, Peter
Hurwitz, Herbert
Text and Data Mining valid from 2014-08-26
Version of Record valid from 2014-08-26
Article History
Received: 30 April 2014
Accepted: 29 July 2014
First Online: 26 August 2014